Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 5—May 2006
Tuberculosis Special Section


Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom

I-Ching Sam*1, Francis Drobniewski*Comments to Author , Philip More*, Melanie Kemp*, and Timothy Brown*
Author affiliations: *Health Protection Agency, London, United Kingdom

Main Article

Table 7

Sequence analysis of 10 discrepant rifampin-susceptibility results*

Sample no. Rifampin susceptibility
LiPA result Phenotypic result Conclusion after sequencing
1–3 Sensitive Resistant From the same patient; wild-type rpoB test region
4 Sensitive Resistant Mycobacterium bovis; wild-type rpoB test region
5–7 Resistant (DS4) Sensitive From the same patient; synonymous substitution (R528R) not associated with rifampin resistance
8 Resistant (DS1) Sensitive 2 genotypes present: wild-type (predominant) and mutant (L511P)
9 Resistant (R5) Sensitive S531L mutation; wild-type rpoB on retesting, thus likely laboratory error
10 Resistant (DS2) Sensitive D516A mutation; no high-level resistance when seen alone

*LiPA, line probe assay.

Main Article

1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO